KARD Stock Forecast: Kardigan, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$12
−7.83% on the day

The median 12-month analyst price target for Kardigan, Inc. is $43. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 3 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$1.1B
Ticker Nerd rank
3/ 100
Median analyst target
$43
Analysts covering
9
Revenue$0.0
Operating income−$75.2M
Net income−$116.2M
Free cash flow−$52.8M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.5%
1M
−14.6%
From high
−55.4%
From low
0.0%
$12
$26
Range since 18 June 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Kardigan, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
3/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
54
Value
16
Growth
10
Issuance
10
Quality
5
Accruals
5
Momentum
5
Volatility
4

Revisions (54): Analysts have, on balance, been raising their forecasts.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KARD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KARD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 18 June 2026Adjusted close, US dollars
$10$20$30$40$50Jul 26Aug 26Sep 26Oct 26Nov 26KARDHigh $50Median $43Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9
Buy
0
Hold
0
Sell
$25
Low
$43
Median
$50
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Nov 2026Leerink PartnersMaintainsOutperform$37 → $36
4 Nov 2026HC Wainwright & Co.InitiatesBuy$42
29 Oct 2026Cantor FitzgeraldInitiatesOverweight$50
22 Oct 2026BairdInitiatesOutperform$43
16 Oct 2026William BlairInitiatesOutperform—
12 Oct 2026UBSInitiatesBuy$25
25 Aug 2026JP MorganMaintainsOverweight$51 → $46
13 July 2026JefferiesInitiatesBuy$40
13 July 2026JP MorganInitiatesOverweight$51
13 July 2026Leerink PartnersInitiatesOutperform$37
13 July 2026TD CowenInitiatesBuy$46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KARD.

Market Radar

This page is one stock. Monday covers all of them.

KARD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KARD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

KARD vs S&P 500, last 12 monthsTotal return, rebased to 100
5060708090100110Jul 26Aug 26Sep 26Oct 26Nov 26KARDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KARD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.9×

Cheaper than 46% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−49.1%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kardigan, Inc. has a market value of $1.1B and an enterprise value of $622.5M.

  • Shares outstanding: 89.3M.

  • Kardigan, Inc. employs 241 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

KARD and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KARDKardigan, Inc.$1.1B3
DRTSAlpha Tau Medical Ltd.$1.1B15
JBIOJade Biosciences, Inc.$1.1B40
VORVor Biopharma, Inc.$1.1B23
SGPSpyGlass Pharma, Inc.$1.0B1
INBXInhibrx Biosciences, Inc.$1.0B37
NKTRNektar Therapeutics$1.0B40

Take a look at KARD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Kardigan, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about KARD

What is the KARD stock price forecast for 2026-2027?

The median 12-month analyst price target for Kardigan, Inc. is $43, with estimates ranging from $25 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KARD stock a buy right now?

Of the 9 analysts covering Kardigan, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kardigan, Inc. 3 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KARD?

As at 21 Nov 2026, Kardigan, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (54 of 100).

Will KARD stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts is $43, and Ticker Nerd's factor model ranks Kardigan, Inc. 3 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KARD stock forecast for 2030?

No analyst covering Kardigan, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KARD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $50 over the next 12 months.

What does Kardigan, Inc. do?

Kardigan Inc. is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company works on targeted therapies designed to address the underlying disease mechanisms behind specific heart conditions, including cardiomyopathies that can lead to heart failure.

Company

About Kardigan, Inc.

Kardigan Inc. is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company works on targeted therapies designed to address the underlying disease mechanisms behind specific heart conditions, including cardiomyopathies that can lead to heart failure. Its current pipeline centers on clinical-stage cardiovascular programs aimed at diseases where approved treatment options remain limited or unavailable. Kardigan also uses a research and translational platform that combines clinical data, analytics, and precision medicine approaches to support drug discovery and development. The company operates as a single segment business centered on cardiovascular therapeutics and serves the broader healthcare and biotechnology market. Kardigan Inc. is headquartered in Princeton, New Jersey, and maintains its operational base in South San Francisco, California.

CEO Mr. Tassos Anastasios E. Gianakakos M.Sc., MBA · 241 employees · United States · https://www.kardigan.bio